Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Pfizer Inc
PFE
Alternate Symbol(s):
N.PFE
Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the...
Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSE:PFE)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on May 09, 2024 10:30am
Two short-timing trials
Yesterday and today on opening or closure..... whith a strong Q1 reports how can we see these tentatives to squeeze it down when revenues are proven and there. this type of market around any stock
...more
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on May 08, 2024 3:23pm
We recuperate the dividend value today
$.42 per share....wow. this stock should be above $30 but just my view. dyodd glta
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on May 07, 2024 2:21pm
Zero traction just to keep its momentum
Ouch not good. Although ex dividend is later this week no need to loose it before the cutoff date.... pfizer has no strength at the moment. Have we touched the bottom? Hopefully yes. glta
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 06, 2024 6:45am
New Press Release - Pfizer Announces New Chief Strategy and Innovation Officer
Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins...
read article.
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on May 03, 2024 9:20am
Stock price Moving average
Here are the stats. We are slowly but surely walking toward the 200 MDA. Period Moving Average Price Change 20-Day 26.10 +0.43
...more
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on May 02, 2024 2:31pm
Q1 results beat expectations
PFE Pfizer Inc. Q1 $0.82 Beat by $0.31 PFE Pfizer Inc. Q1
...more
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on May 01, 2024 2:22pm
Trading volume today
We are way higher than the average 42 millions shares per day we are at 55 million and keep increasing. this is very good with a 6% stock price increase. we have the real W shape and it is going up
...more
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on May 01, 2024 10:26am
Excellent Quarterly report
And here we go, up up and probably up... and ex dividend date coming soon. glta dyodd
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 01, 2024 6:45am
New Press Release - Pfizer Reports First-Quarter 2024 Results
Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities First-Quarter 2024 Revenues of $14.9 Billion Expected Decline in Comirnaty(1) and Paxlovid Revenues Drove a Year-Over-Year Operational Decrease in Revenues of 19% Excluding...
read article.
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 30, 2024 8:55pm
1998 value , $25
Difficult to understand and on top maximum inflation lately. So if you put it in constant dollar, this is a disaster. Bagholders are suffering and they need a vaccine... what will trigger a small leg
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 29, 2024 6:40pm
New Press Release - TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Company AnnouncementFull approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 29, 2024 6:40pm
New Press Release - FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancerConversion to full approval from accelerated approval is based on positive results from global Phase 3 study demonstrating overall...
read article.
(174)
•••
ecolo101
X
View Profile
View Bullboard History
Post by
ecolo101
on Apr 29, 2024 10:19am
Let’s hope for a W shape
Starting right now.... Pfizer should do way better than this on stock price. We should be around $30 by now... dyodd
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 29, 2024 6:45am
New Press Release - Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
More than 50 abstracts, including 11 oral presentations, span Pfizer’s robust portfolio of approved and pipeline therapies across its key tumor areas and core scientific modalitiesNew five-year progression-free survival data for LORBRENA® (lorlatinib) in first-line ALK-positive advanced lung...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >